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Abstract KCNE1 encodes the β-subunit of the slow
component of the delayed rectifier K
+ current. The Jervell
and Lange-Nielsen syndrome is characterized by sensori-
neural deafness, prolonged QT intervals, and ventricular
arrhythmogenicity. Loss-of-function mutations in KCNE1
are implicated in the JLN2 subtype. We recorded left
ventricular epicardial and endocardial monophasic action
potentials (MAPs) in intact, Langendorff-perfused mouse
hearts. KCNE1
−/− but not wild-type (WT) hearts showed
not only triggered activity and spontaneous ventricular
tachycardia (VT), but also VT provoked by programmed
electrical stimulation. The presence or absence of VT was
related to the following set of criteria for re-entrant
excitation for the first time in KCNE1
−/− hearts: Quantifi-
cation of APD90, the MAP duration at 90% repolarization,
demonstrated alterations in (1) the difference, ∆APD90,
between endocardial and epicardial APD90 and (2) critical
intervals for local re-excitation, given by differences
between APD90 and ventricular effective refractory period,
reflecting spatial re-entrant substrate. Temporal re-entrant
substrate was reflected in (3) increased APD90 alternans,
through a range of pacing rates, and (4) steeper epicardial
and endocardial APD90 restitution curves determined with a
dynamic pacing protocol. (5) Nicorandil (20 µM) rescued
spontaneous and provoked arrhythmogenic phenomena in
KCNE1
−/− hearts. WTs remained nonarrhythmogenic. Nic-
orandil correspondingly restored parameters representing
re-entrant criteria in KCNE1
−/− hearts toward values found
in untreated WTs. It shifted such values in WT hearts in
similar directions. Together, these findings directly impli-
cate triggered electrical activity and spatial and temporal re-
entrant mechanisms in the arrhythmogenesis observed in
KCNE1
−/− hearts.
Keywords Mice.Actionpotentialduration.Ventricular
arrhythmogenesis.Re-entry
Introduction
Ventricular tachycardia (VT) is an important cause of
morbidity and mortality accounting for 80% of the annual
50,000–70,000 cases of sudden cardiac death (SCD) in the
UK [36] and over 300,000–400,000 cases in the USA [77].
A subset of these deaths is caused by an inherited
predisposition to VT of which congenital long QT
syndrome (LQTS) forms an important genetically transmit-
ted category with a prevalence recently estimated at one in
2,500 live births [8].
LQTS patients have been classified according to their
mode of transmission into the autosomal recessive Jervell
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Boston, MA 02115, USAand Lange-Nielsen (JLN) syndrome [20] or the autosomal
dominant Romano–Ward (RW) syndrome [43, 71]. Jervell
and Lange-Nielsen in 1957 provided the first report of
LQTS in their description of a Norwegian family with four
out of six children having deaf-mutism, prolonged electro-
cardiographic QT intervals, syncopal episodes, and sudden
death. JLN and RW syndromes are thus additionally
differentiated phenotypically by the congenital bilateral
sensorineural deafness that afflicts patients with JLN
syndrome but not RW syndrome [20, 43, 71]. Since the
first report of LQTS, a wide range of LQTS subtypes
have been discovered (reviewed by [6]). All of these affect
ion channels or proteins that interact with ion channels,
predisposing patients to potentially lethal ventricular
arrhythmias, syncope, SCD, characteristic prolonged electro-
cardiographic QT intervals, and in some cases, T wave
abnormalities [8, 54]. Such conditions provide opportunities
to study mechanisms of arrhythmia resulting from defined
genetic abnormalities.
The KCNE1 gene encodes a 129-amino acid protein,
minK, an accessory β-subunit that, together with KvLQT1
α-subunits (encoded by the KCNQ1 gene), form the slow
component [5, 49] of the delayed rectifier K
+ current in
cardiac myocytes [37, 38]. Autosomal dominant heterozy-
gous mutations in the KCNE1 gene may result in the long
QT 5 syndrome [62]. More marked reductions in IKs
resulting from homozygous or compound heterozygous
mutations in KCNQ1 or KCNE1 can give rise to the
characteristic JLN syndrome [35, 53, 61, 67]. JLN
syndrome has, therefore, been classified into JLN1 and
JLN2, distinguishing between associated mutations in
KCNQ1 or KCNE1, respectively [6]. Loss-of-function
mutations in KCNE1, which may give rise to LQT5 or
JLN2 are thus associated with reduced K
+ currents and
compromised repolarization reserve.
Further experimental studies exploring for mecha-
nisms of arrhythmogenesis and potential therapeutic
approaches in JLN syndrome, with due attention to the
gene in which the primary genetic abnormality resides,
are thus of significant interest. Such gene-specific
investigations of JLN syndrome at the experimental
level are warranted, firstly, in view of the fact that the
J L N 1a n dJ L N 2v a r i a n t s ,b o t hp a r t i c u l a r l ys e v e r ef o r m s
of LQTS [56], while clinically similar [67], have
mutations in distinct genes. Secondly, JLN syndrome is
rare, with an estimated incidence of 1.6 to six cases per
million [10]. Thirdly, besides involving β-subunits rather
than α-subunits of the channels concerned, KCNE1
−/−
mutations accounted for 9.5% of patients with JLN
syndrome that could be successfully genotyped in a recent
clinical review [56]. There is, therefore, limited knowl-
edge about the mechanisms involved and possible thera-
peutic approaches in both JLN syndrome and JLN2 in
particular. Finally, there are potential therapeutic implica-
tions for studying JLN syndrome according to the
underlying genetic abnormality in view of a range of
treatment options for LQTS, including pharmacological
approaches such as β-blockers, as well as pacemakers, left
cervicothoracic sympathectomy, and implantable cardiac
defibrillators [42]. Nevertheless, as many as 51% of
patients with JLN syndrome experience arrhythmic events
despite current treatment options [56]. Together with
current suggestions for genotype-targeted therapy [33],
these considerations warrant correspondingly genotype-
targeted investigations of arrhythmogenic mechanisms in
the JLN variants.
Mouse models have previously provided good para-
digms for a variety of genetic cardiac arrhythmia conditions
[27]. They have also permitted systematic identification and
separation of the contrasting contributions made by ectopic
and re-entrant arrhythmogenic mechanisms, as well as
spatial and temporal components contributing to re-entry
[16, 17, 23, 25, 65]. A mouse model of JLN2 has been
developed previously by targeted homozygous deletion of
the KCNE1 gene [68]. This model replicates the primary
abnormalities observed in the human JLN syndrome in
showing inner ear defects [9] manifesting as shaker/waltzer
movement disorders, as well as an increased tendency to
ventricular arrhythmias compared to wild-type (WT) hearts
[4, 66].
The present study accordingly examined potential trans-
mural mechanisms for ventricular arrhythmogenesis in this
mouse model of JLN2 at the isolated whole organ level. We
made monophasic action potential (MAP) recordings for
quantitative analyses of changes in action potential wave-
forms in isolated whole hearts. This thus complemented
previous electrocardiographic studies in intact animals [9]
in allowing for assessments of intrinsic cardiac properties
independent of autonomic factors while preserving inter-
cellular coupling and spatial electrophysiological character-
istics. This permitted recordings of localized epicardial and
endocardial waveforms in contrast to electrocardiographic
studies that would have only represented voltage differ-
ences summed across the entire myocardium. Thus, it was
possible to apply to KCNE1
−/− hearts experimental tests
applied on a previous occasion in a murine model for LQT3
[17]. This made it possible to identify tendencies for
spontaneous arrhythmogenicity manifesting as triggered
activity and spontaneous VT, as well as assessing for
provoked arrhythmogenic tendencies [65]. It also made it
possible to systematically apply and quantify criteria for
spatial re-entrant substrates [3] in the form of altered
∆APD90 [25, 64] and local critical intervals for re-excitation
[44]. Finally, we could quantify criteria for temporal
substrates [72, 73] through a description of APD90 alternans
and APD90 restitution properties [16, 45].
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logical manipulations on all of these criteria as well as upon
the observed arrhythmogenicity. Such experiments involved
comparison of these features in both KCNE1
−/− and WT
hearts in the presence or absence of nicorandil. Preliminary
clinical reports had suggested that nicorandil may be
antiarrhythmic in clinical LQTS [1, 13, 50, 58], though
this has not been investigated in the setting of LQTS
specifically due to KCNE1 mutations. Similar suggestions
have also arisen from animal studies using experimental
models of LQT1, LQT2, and LQT3 in the canine wedge
[57], LQT1 in the guinea pig [76], and in a LQT model
induced by disopyramide pretreatment [12] in all of which
repolarization had been delayed by pharmacological manip-
ulations but have not been investigated in any arrhythmo-
genic model based upon KCNE1 abnormalities.
An assessment of the effects of nicorandil in a model for
JLN2 is important as pharmacological agents that are
antiarrhythmic in one particular LQTS subtype may not
act similarly in other subtypes [55]. Nicorandil could
potentially offset the delayed repolarization resulting from
reduced delayed K
+ current observed in JLN in view of
previous descriptions of nicorandil-mediated reductions in
myocardial APD90 in different cardiac preparations. The
concentrations of nicorandil used in this study (100 nM to
20 µM) were based on established literature that has
demonstrated such empirical actions of nicorandil in a
variety of cardiac preparations. This may be through actions
providing an enhanced repolarization reserve through
increased K
+ conductance [18, 22, 57, 60]. Nicorandil
causes significant APD90 shortening at the cellular level at
concentrations of 10 µM in left atrial muscle fibres [74], 1,
10, 30, and 100 µM in Purkinje fibres [18, 31, 75], and 10
and 100 µM in isolated guinea pig and rabbit ventricular
myocytes [15, 22] independently of external [Na
+][ 18],
and in the absence of alterations in Ca
2+ currents [15, 22],
maximum upstrokes of the action potential [18, 22] and
maximum diastolic membrane potentials ([15, 18, 31] but
see [74]). It also shortens APD90 at the tissue [57, 76] and
whole organ [26] levels at 2 to 20 µM in canine LQT1,
LQT2, and LQT3 pharmacological models [57], at 5 to
30 µM in guinea pig hearts in the absence or presence of
chromanol 293B [76], at 20 µM in murine hypokalaemic
hearts [26], and at 10 to 20 µM in murine Scn5a+/∆KPQ
hearts modeling LQT3 [17].
The present findings establish empirically for the first
time that nicorandil may have a useful antiarrhythmic role
as reflected in its suppression of triggered activity,
spontaneous VT, and provoked VT. They also demonstrate
a parallel modification of recently introduced quantitative
indicators of both spatial and temporal re-entrant substrates
[16]. In so doing, these studies also demonstrate an
existence of abnormal restitution properties in the
KCNE1
−/− system for the first time. Together, these findings
implicate such features in the arrhythmogenic properties
observed in KCNE1
−/− hearts.
Materials and methods
Experimental animals
KCNE1
−/− mice were supplied by Vetter et al. [68] and
inbred upon the 129/Sv background. Breeding pairs of
homozygotes and WTs were established and gave rise to
lines of KCNE1
−/− and WT animals. Mice were housed at
21±1°C with 12 h light/dark cycles. Mice were fed sterile
chow (RM3 Maintenance Diet, SDS, Witham, Essex, UK)
and had free access to water at all times. Randomly selected
male and female mice aged 5–7 months were used for
experiments. All procedures conformed to the UK Animals
(Scientific Procedures) Act 1986.
Heart isolation
A Langendorff-perfusion technique was used as previously
described [14]. Mice were killed by cervical dislocation
(Schedule 1: Animals (Scientific Procedures) Act 1986).
Hearts were exposed by bilateral sternotomy, rapidly
excised, and a small section (3–4 mm) of aorta was
identified and cannulated in ice-cold, Krebs–Henseleit
solution using a custom-made 21-gauge cannula and
secured using an aneurysm clip (Harvard Apparatus,
Edenbridge, Kent, UK). Krebs–Henseleit solution con-
sisted of (in mM): NaCl 119, NaHCO3 25, KCl 4,
KH2PO4 1.2, MgCl2 1, CaCl2 1.8, glucose 10, and Na
pyruvate 2, pH 7.4, bubbled with 95% O2/5% CO2 (British
Oxygen Company, Manchester, UK). The isolated hearts
were then transferred within 120 s from excision to the
Langendorff-perfusion system. They were perfused retro-
gradely with Krebs–Henseleit solution via the coronary
arteries at a flow rate of 2.0–2.5 mL/min using a peristaltic
pump (Watson-Marlow Bredel Model 505S, Falmouth,
Cornwall, UK). The perfusate had been passed through
two, 200- and 5-mm, filters (Millipore, Watford, UK) and
then heated to 37°C by a water-jacketed heat-exchange coil
and circulator (Ecolin Staredition E100, Lauda, Lauda-
Königshofen, Germany). Healthy hearts regained a healthy
pink colour and contracted spontaneously. Approximately
10% of hearts were discarded due to signs of ischaemia.
Perfused heart electrophysiology
MAPs were recorded from the epicardial and endocardial
surfaces of the left ventricular free wall. Epicardial record-
ings were made with a MAP electrode (Linton Instruments,
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positioned against the basal left ventricular epicardial
surface. Endocardial recordings were made using a
custom-made MAP electrode constructed from Teflon-
coated silver wire of 0.25 mm diameter (Advent Research
Materials, UK) and 99.99% purity. The final 1 mm of
Teflon coating was removed from the electrode tips, which
were then galvanically chlorided to avoid DC offset. An
aperture was carefully made in the interventricular septum
to allow the electrode to be positioned against the left
ventricular endocardial free wall. MAP waveforms were
quantified to determine APDx, the time taken for repolar-
ization to x%, thus permitting the quantification of APD30,
APD50, APD70, and APD90. MAPs met previously estab-
lished criteria including a rapid upstroke, smooth contoured
repolarization phase, and a stable baseline [28]. Peak
depolarization (0% repolarization) was considered to be
the most positive point of deflection above the baseline,
while 100% repolarization was considered to be the point
of return to baseline [25]. MAP signals were preamplified
with a NL100AK head stage and band pass filtered
(0.5 Hz to 1 kHz; Neurolog NL 125/6 Filter, Neurolog,
Hertfordshire, UK). A micro 1401plus MKII laboratory
interface (Cambridge Electronic Design, Cambridge, UK)
was used to digitize these signals at a sampling frequency
of 5 kHz. Spike2 software (Cambridge Electronic Design,
Cambridge, UK) was used to analyze MAP waveforms.
Experimental protocol
Hearts were stimulated from the basal right ventricular
epicardium with a bipolar platinum electrode with 1 mm
interpole distance. Square-wave stimuli (Grass S48 Stimu-
lator, Grass-Telefactor, Slough, UK) of 2 ms duration and
three times the diastolic threshold [25] were applied at a
basic cycle length (BCL) of 125 ms corresponding to
murine whole heart physiological heart rates [41]. Hearts
were initially paced for at least 10 min at a constant BCL of
125 ms to reach a steady-state. Following this initial
equilibration period, both spontaneous and provoked
arrhythmogenesis were assessed in the absence and
presence of nicorandil. VT was defined as five or more
consecutive premature MAPs [25]. Spontaneous arrhyth-
mogenic properties were assessed in the absence of
extrinsic pacing. Provoked arrhythmogenesis was assessed
using a programmed electrical stimulation (PES) method
adapted from clinical practice [51] and previously applied
to murine hearts [14]. The PES protocol consisted of cycles
of 8 S1 stimuli applied at a BCL of 125 ms, followed by a
S2 extrastimulus. The S1-S2 stimulus interval began at
125 ms and decreased by 1 ms with each successive cycle
of eight S1 stimuli. This extrasystolic protocol also enabled
the quantification of ventricular effective refractory periods
(VERPs) from the longest S1–S2 interval that failed to
elicit a MAP. Action potential durations (APDs) and
stimulus-depolarization conduction latencies were quanti-
fied during steady-state pacing at a 125 ms BCL [25, 64]. A
dynamic pacing protocol (see the “Results” section) was
used to assess temporal properties allowing the examination
of APD90 alternans and APD90 restitution properties.
Pharmacological agents
Drug-containing solutions were made by adding nicorandil
(Tocris Bioscience, UK) from 10 mM stock solutions made
up in doubly distilled water, to Krebs–Henseleit solution,
and serially diluted to the target concentrations (100 nM,
1 µM, 10 µM, and 20 µM).
Data analysis and statistics
Data are presented as the means±standard error of the
means together with the number of hearts (n). Categorical
data were compared using Fisher’s exact test (one-tailed),
and continuous data were compared using analysis of
variance (SPSS software) and Student’s unpaired t test as
appropriate. P values less than 0.05 were considered
significant. Curve fitting to experimental restitution data
sets was performed using a Levenberg–Marquardt algo-
rithm (Origin 8, OriginLab, MA, USA).
Results
Langendorff preparations of murine hearts were initially
perfused using control Krebs–Henseleit solution and MAP
recordings were then made following 10 min of such
perfusion. Recordings made in the presence of nicorandil
were similarly made following 10 min of perfusion with
nicorandil-containing Krebs–Henseleit solution. Hearts
were first investigated during intrinsic activity for assess-
ment of spontaneous arrhythmogenic properties. They were
then investigated for provoked arrhythmogenesis using a
PES protocol [4]. MAP waveforms were recorded and
assessed from the left ventricular epicardium and endocar-
dium during steady-state 8-Hz pacing as on previous
occasions in the mouse heart [16, 25]. Finally, dynamic
repolarization properties were investigated using a dynamic
pacing protocol.
Triggered activity and spontaneous arrhythmogenesis
in intrinsically beating KCNE1
−/− hearts
Intrinsically beating KCNE1
−/− hearts perfused with control
solution demonstrated triggered activity, observed as
ectopic MAP waveforms in nine out of ten hearts
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following or just prior to MAP repolarization in agreement
with the timing of afterdepolarization phenomena described
on earlier occasions [19, 23]. These abnormalities were
absent in intrinsically beating WT hearts (n=5) (Fig. 1b).
We then tested the effect of nicorandil upon the occurrence
of triggered activity. Nicorandil (20 µM) suppressed
triggered activity in KCNE1
−/− hearts (Fig. 1c), while in
WT hearts, there remained a total absence of such triggered
electrical activity (n=7 and 5, KCNE1
−/− and WT hearts,
respectively) (Fig. 1d).
Following these preliminary observations of the effects
of 20 µM nicorandil, we proceeded to investigate the effect
of a range of nicorandil concentrations (100 nM, 1 µM,
10 µM, and 20 µM) upon triggered activity in intrinsically
beating hearts. The incidence of such activity was deter-
mined from randomly selected 10 s sampling periods in
each heart at any given nicorandil concentration from MAP
recordings in each heart (consisting of 211±67 and 337±80
MAPs per heart, WT and KCNE1
−/−, respectively). Nicor-
andil treatment was associated with a concentration-
dependent reduction in the incidence of triggered activity
in KCNE1
−/− hearts. Thus, the proportion of ectopic MAP
waveforms decreased from 28.1±8.4% in hearts perfused
with control solution (n=10) to 20.9±10.9% at 100 nM (n=
5, P>0.05), 20.5±10.9% at 1 µM (n=5, P>0.05), 2.2±
2.1% at 10 µM (P<0.05; n=5), and 0.9±1.1 at 20 µM
nicorandil (P<0.01; n=7) (all comparisons performed
against untreated hearts). WT hearts did not show triggered
activity anywhere in the range of nicorandil concentrations
(n=5 at each concentration).
These ectopic waveforms frequently occurred in associ-
ation with runs of spontaneous VT, defined as five or more
premature MAP waveforms [25], in intrinsically beating
KCNE1
−/− hearts (Fig. 1a). The incidence of VT was
determined by analyzing MAP waveforms recorded from
such intrinsically beating hearts. Spontaneous VT occurred
in six out of ten untreated KCNE1
−/− versus none out of
five untreated WT hearts, demonstrating a significant
tendency to spontaneous VT in KCNE1
−/− compared to
WT hearts (P<0.05; Fisher’s exact test). In contrast, during
treatment with nicorandil (20 µM), spontaneous VTwas not
seen in any KCNE1
−/− or WT hearts (n=7 and 5, for
KCNE1
−/− hearts and WT hearts, respectively), demonstrat-
ing a significant antiarrhythmic effect of nicorandil upon
spontaneous VT (P<0.05; Fisher’s exact test).
Provoked arrhythmogenesis in KCNE1
−/− hearts
We then investigated tendencies to provoked arrhythmo-
genesis using an established PES protocol adapted from
clinical practice [51] and successfully applied in murine
cardiac systems [4, 41]. The protocol consisted of cycles of
eight S1 stimuli at a frequency of 8 Hz, with each cycle
followed by an extrastimulus, S2, initially 125 ms after the
preceding S1 stimulus. This S1–S2 stimulus was then
progressively reduced by 1 ms with each cycle until hearts
were either refractory to the S2 or VT was initiated. PES
resulted in VT in five out of five untreated KCNE1
−/− hearts
(Fig. 2a) in contrast to none of five untreated WT hearts
that were totally refractory to such provocation (Fig. 2b).
We then assessed the effect of a range of concentrations of
Fig. 1 Representative MAP recordings from intrinsically beating
KCNE1
−/− hearts Langendorff-perfused with control Krebs–Henseleit
solution demonstrating typical spontaneous triggered activity occur-
ring as ectopic MAP waveforms (asterisk) in association with the
onset of spontaneous VT (a) in contrast to their absence in similarly
perfused intrinsically beating WT hearts (b). Treatment with 20 µM
nicorandil reduced both triggered activity and VT in KCNE1
−/− hearts
(c). WT hearts treated with nicorandil did not show triggered activity
or VT (d)
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arrhythmogenicity. PES resulted in VT in five out of five
hearts at 100 nM and 1 µM nicorandil. Higher concen-
trations of nicorandil (10 and 20 µM) reduced this
incidence to one out of five hearts (Fig. 2c), demonstrating
a significant antiarrhythmic effect against PES-induced
arrhythmogenesis (P<0.05 versus untreated hearts; Fisher’s
exact test). WT hearts remained refractory to provocation
by PES at all concentrations used (Fig. 2d) (n=5).
Previous reports have described sex-linked differences in
arrhythmogenic phenotype in a number of congenital
arrhythmic conditions [2]. Our study did not detect
significant differences in findings between male and female
KCNE1
−/− hearts. Thus, triggered activity was seen in six of
seven male and three of three female untreated hearts.
Spontaneous VT was seen in four of seven males and two
of three females. PES induced VT in three of three males
and two of two females. This is consistent with a previous
report [4] that investigated KCNE1
−/− hearts with bipolar
electrograms, but not MAP recordings, in which untreated
KCNE1
−/− hearts were all arrhythmic (five males and five
females) with PES. Our results showed that nicorandil
(20 µM) produced similar actions upon KCNE1
−/− mice
whether male or female. Triggered activity was observed in
just one of five male and zero of two female nicorandil-
treated hearts. Spontaneous VTwas observed in zero of five
males and zero of two females studied. VT was then
provoked by PES in one of three male and zero of two
female hearts. In contrast, none of two male and three
female untreated WT hearts showed evidence for triggered
activity or spontaneous VT. None of three male and two
female untreated WT hearts showed PES-induced VT.
Following the introduction of 20 µM nicorandil, none of
two male and three female hearts showed either triggered
activity or spontaneous VT, nor did any of two male or three
female WT hearts show PES-induced VT. Furthermore,
there was no evidence for sex-linked differences in VERP in
either KCNE1
−/− or WT hearts. Thus, male and female
animals gave VERPs of 28.8±2.7 and 30.5±5.1 ms in
KCNE1
−/− hearts and 25.6±2.5 and 27.5±3.5 ms in WT
hearts, respectively. Following the addition of nicorandil,
the respective values were 32.0±3.2 and 28.0±9.0 ms in
KCNE1
−/− and 25.7±0.5 and 29.5±2.5 ms in WT hearts,
respectively.
Epicardial and endocardial MAP waveforms in WT
and KCNE1
−/− hearts
Previous studies have investigated epicardial and endocar-
dial action potential waveforms in murine models of
inherited LQTS [64, 65] and hypokalaemic LQTS [23, 25]
and suggested that alterations in the durations of epicardial
waveforms compared to endocardial waveforms may be
associated with altered arrhythmogenic tendencies. We,
therefore, proceeded to quantify APDs in both untreated
and nicorandil-treated hearts to investigate the underlying
basis of arrhythmic phenomena for the first time in
KCNE1
−/− hearts. Representative epicardial and endocardial
MAP waveforms in WT and KCNE1
−/− hearts recorded in
the absence and presence of 20 µM nicorandil are shown in
Fig. 3. This demonstrates the typically prolonged epicardial
MAP waveform in KCNE1
−/− compared to WT hearts and
Fig. 2 MAP recordings obtained during a PES protocol used to assess
for provoked arrhythmogenic tendencies. They demonstrate the
typical initiation of VT in untreated KCNE1
−/− hearts observed in
five out of five hearts (a) and the prevention of such VT by treatment
with nicorandil (20 µM) in four out of five hearts (P<0.05) (c). WT
hearts were refractory to PES provocation whether untreated (b)o r
treated with nicorandil (d)
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in both KCNE1
−/− and WT hearts perfused with nicorandil.
APDs at x% repolarization (APDx) were quantified during
steady-state 8 Hz extrinsic pacing (Fig. 4) approximating
typical physiological murine heart rates [41]. In the
epicardium of untreated KCNE1
−/− hearts, APD90 and
APD70 were significantly longer than in the epicardium of
untreated WT hearts. Thus, APD90 was 55.1±1.0 versus 40.
9±1.5 ms (P<0.001; n=5 and 5) and APD70 was 30.7±1.9
versus 21.4±1.4 ms (P<0.01; n=5 and 5) in KCNE1
−/− and
WT hearts, respectively. In contrast to these epicardial
findings, there was no difference in endocardial APD
between untreated KCNE1
−/− and WT hearts. Endocardial
APD90 was 51.3±1.4 and 51.0±1.2 ms in untreated
KCNE1
−/− and WT hearts, respectively (P>0.05; n=5 in
both cases).
We also determined the effect of a range of concen-
trations of nicorandil (100 nM, 1 µM, 10 µM, and 20 µM)
upon APD in KCNE1
−/− hearts. In the epicardium of
KCNE1
−/− hearts, APD90 was reduced by nicorandil to
51.1±0.9, 44.5±2.2, and 38.9±1.8 ms during treatment
with 1, 10, and 20 µM nicorandil (P<0.05, P<0.001, and
P<0.001 versus untreated KCNE1 hearts at 1, 10, and
20 µM, respectively). In WT hearts, epicardial APD90 was
also shortened by nicorandil to 35.6±1.5 and 33.8±0.9 ms
at 10 and 20 µM nicorandil, respectively (10 µM, P<
0.05; 20 µM, P<0.001; n=5 in all cases). In contrast,
endocardial APD90 was not changed by nicorandil in either
KCNE1
−/− or WT hearts. Thus, during perfusion with
20 µM nicorandil, endocardial APD90 was 53.5±1.5 and
50.6±1.2 ms in KCNE1
−/− and WT hearts, respectively (n=
5 in all cases; P>0.05 versus untreated hearts of the same
genotype).
These findings demonstrate preferential abnormalities
in epicardial APD90 and conserved endocardial APD90 in
parallel with increased arrhythmic tendencies in untreated
KCNE1
−/− hearts. These findings together complement
previous observations in a model of LQT3 [64]a n dt h e
hypokalaemic murine heart [25]. The present findings
further show that nicorandil altered these KCNE1
−/−
MAP waveform characteristics toward those found in
untreated WTs.
Transmural gradients of repolarization in WTand KCNE1
−/−
hearts
The ventricular wall has been shown to possess
heterogeneities in APD, not only in the murine heart
[69] but also in larger hearts such as the canine heart [3]. It
has been suggested that such regional differences in APD
are due to heterogeneities in spatial patterns of repolari-
zation [3] resulting from transmural gradients of ion
channel expression [52] .I nt h em u r i n es y s t e m ,t h et r a n s -
mural gradient of repolarization, ∆APD90, given by the
difference between endocardial and epicardial APD90,h a s
been used to explore for spatial substrates for re-entrant
excitation [24, 25].
We initially determined epicardial and endocardial
activation times, which reflect the time taken from
ventricular electrical stimulation to peak depolarization.
We were able to quantify activation times from MAP
recordings by measuring the latent period between electri-
cal stimulation and the peak of the MAP. Activation times
were 17.3±1.3 and 16.4±1.7 ms in the epicardium and
endocardium of untreated KCNE1
−/− hearts, respectively,
and did not significantly differ. Activation times were
16.1±1.1 and 17.9±1.1 ms in the epicardium and endocar-
dium ofuntreatedWT hearts(n=5 in all cases), respectively,
which also did not differ significantly. Following treatment
with 20 µM nicorandil, activation times in the epicardium
and endocardium were 16.8±1.2 and 17.4±1.3 ms in
KCNE1
−/− hearts and 19.1±1.8 and 15.7±1.0 ms in the
epicardium and endocardium of WT hearts (n=5 in all
Fig. 3 Representative MAP waveforms during steady-state 8-Hz
pacing recorded from the left ventricular epicardia and endocardia of
KCNE1
−/− (a and c) and WT (b and d) hearts perfused with control
solution (a and b) or 20 µM nicorandil (c and d). KCNE1
−/− hearts
had longer epicardial MAP waveforms (a) than WTs similarly
perfused with control solution (b), and both were shortened by
nicorandil (c and d) while endocardial MAPs were conserved in both
(c and d)
Pflugers Arch - Eur J Physiol (2009) 458:819–835 825cases), respectively, which also did not differ significantly.
Finally, epicardial or endocardial activation times both did
not differ between KCNE1
−/− and WT hearts, whether in
untreated hearts or in those treated with 20 µM nicorandil.
Thus, changes in arrhythmogenicity were not associated
with detectable changes in activation times. Furthermore, in
the absence of significant differences in activation times,
we were able to represent the transmural gradient of
repolarization by ΔAPD90 as on previous occasions in the
murine heart [16, 25].
Figure 5 shows the ∆APD90 values for KCNE1
−/− and
WT hearts in the absence and presence of nicorandil. In
untreated KCNE1
−/− hearts, ∆APD90 was −3.8±1.7 ms (n=
5), significantly smaller (P<0.001) than in untreated WT
hearts where ∆APD90 was 10.9±1.9 ms (n=5). Nicorandil
resulted in a concentration-dependent increase in ∆APD90
in KCNE1
−/− hearts, reaching significance at 10 and 20 µM
nicorandil, with ∆APD90s of 5.1±2.9 and 14.6±2.4 ms at
10 and 20 µM, respectively (10 µM, P<0.05; 20 µM,
P<0.001). This concentration range was similar to that at
which spontaneous and provoked arrhythmogenic phenom-
ena were reduced and at which epicardial APD90 was
shortened. In WT hearts, nicorandil also concentration-
dependently increased ∆APD90 in WT hearts, reaching
statistical significance at 10 and 20 µM. In WT hearts,
Fig. 4 APD at 30%, 50%, 70%, and 90% repolarization quantified
from MAP recordings made from the epicardium of KCNE1
−/− (a) and
WT (b) hearts during 8-Hz extrinsic pacing demonstrated a
concentration-dependent reduction in APD90 and APD70 with nicor-
andil. In contrast, similarly obtained MAP recordings from the
endocardium of KCNE1
−/− (c) and WT (d) hearts demonstrated
conserved APD values during perfusion with nicorandil (*P<0.05;
**P<0.01; ***P<0.001)
Fig. 5 The transmural gradient of repolarization, ∆APD90, determined
from endocardial and epicardial MAP recordings during 8-Hz
extrinsic pacing through a range of nicorandil concentrations in
KCNE1
−/− (a) and WT hearts (b)( * P<0.05; ***P<0.001)
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(n=5) at 10 and 20 µM nicorandil (P<0.05 in both cases),
respectively.
Critical intervals for local re-excitation in WTand KCNE1
−/−
hearts
Recent studies in the hypokalaemic murine heart have
suggested that the interval between APD90 and VERP
reflects the likelihood for local re-excitation and that
reductions in this interval may be antiarrhythmic [44]. We
accordingly investigated this relationship in KCNE1
−/−
hearts for the first time. Figure 6 shows such critical
intervals over a range of nicorandil concentrations in
hearts paced at 8 Hz. In untreated KCNE1
−/− hearts, the
epicardial critical interval was significantly greater than in
untreated WT hearts, 25.3±3.3 versus 14.7±2.2 ms in
KCNE1
−/− and WT hearts, respectively (P<0.05; n=5).
We then investigated the effect of nicorandil upon such
intervals (Fig. 6). Nicorandil produced a concentration-
dependent reduction in local critical intervals for re-
excitation, reaching significance at 20 µM nicorandil with
a critical interval of 8.2±3.8 ms (P<0.01 versus untreated
KCNE1
−/− hearts; n=5). Nicorandil also produced
concentration-dependent reductions in critical intervals in
WT hearts, reaching significance at 20 µM with a critical
interval of 7.5±2.4 ms (P<0.05 versus untreated WT
hearts; n=5). Thus, the enhanced arrhythmogenicity in
KCNE1
−/− hearts compared to WT hearts was accompa-
nied by larger critical intervals for local re-excitation.
Furthermore, nicorandil produced reductions in local
critical intervals in parallel with its antiarrhythmic effect
in KCNE1
−/− hearts and alongside the lack of arrhythmia
inducibility in WT hearts.
The magnitude of APD90 alternans in WT and KCNE1
−/−
hearts
Alternations in APD90 have been associated with a
variety of arrhythmias in human [54] and animal studies
[45]. We used a dynamic pacing protocol to assess APD90
properties over a range of BCLs [29]. This protocol
consisted of cycles consisting of 100 stimuli at each BCL,
starting with a BCL of 190 ms and reduced by 5 ms
decrements with each successive cycle down to a final
BCL of 65 ms. The final 50 action potentials within each
cycle of 100 action potentials at any particular BCL
yielded steady-state recordings that were analyzed to
determine APD90 values, as in a previous study in the
hypokalaemic murine heart [45]. Firstly, in all hearts,
alternans in both epicardial and endocardial MAPs
increased as BCL decreased (Fig. 7). Secondly, successive
values of APD90 alternans in untreated KCNE1
−/− hearts
(Fig. 7, squares) tended consistently to fall above
corresponding points obtained in WT hearts (Fig. 7,
triangles) through the investigated range of BCLs. This
trend applied for both epicardial (Fig. 7a) and endocar-
dial values (Fig. 7b). Finally, treatment with 20 µM
nicorandil reduced such differences in alternans between
KCNE1
−/− and WT hearts in both epicardium (Fig. 7c) and
endocardium (Fig. 7d).
APD90 restitution properties in WT and KCNE1
−/− hearts
Increases in the steepness of APD90 restitution curves have
been reported to associate with enhanced arrhythmogenicity
in both clinical reports [40, 63] and experimental systems
[29, 45]. APD90 restitution properties have been investigat-
ed by plotting APD90 versus the preceding diastolic interval
(DI) [39]. We accordingly proceeded to investigate restitu-
tion properties in KCNE1
−/− hearts and constructed APD90
restitution curves using experimental data obtained from
both epicardium and endocardium using a dynamic pacing
protocol for the first time in this system, thereby allowing
comparison with other murine arrhythmic models to which
this method has been applied [16, 45]. Furthermore, we
then tested the effect of nicorandil on APD90 restitution
properties in any model of JLN for the first time.
Fig. 6 Comparison of epicardial APD90, VERP, and local critical
intervals for re-excitation measured during steady 8-Hz extrinsic
pacing over a range of nicorandil concentrations in the epicardium of
KCNE1
−/− (a) and WT (b) hearts (*P<0.05; **P<0.01; ***P<0.001).
APD90 data set from Fig. 4
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epicardium of KCNE1
−/− and WT hearts perfused with
either control solution or after treatment with 20 µM
nicorandil. Similarly obtained restitution curves obtained
from the endocardium of KCNE1
−/− and WT hearts
perfused with either control solution or after treatment with
20 µM nicorandil are shown in Fig. 9.
Such curves were fitted with a monoexponential curve
[16, 45] of the form:
y ¼ y0 þ A 1   e x=t 
: ð1Þ
Empirical data points were fitted using a Levenberg–
Marquardt algorithm [16, 45]. The gradients of the fitted
functions are also shown in Figs. 8 and 9, given by the
following function:
dy
dx
¼
A
t
e x=t: ð2Þ
The parameters used in curve fitting for the epicardial
and endocardial restitution data sets are shown in
Tables 1 and 2.
Restitution curves in KCNE1
−/− and WT hearts show
contrasting critical diastolic intervals and maximum
gradients
The slopes of restitution curves obtained under the different
experimental conditions were quantified and summarized in
Tables 1 and 2. This analysis showed that, in the absence of
nicorandil, KCNE1
−/− hearts possessed steeper gradients of
restitution curves than WT hearts as assessed by both their
critical diastolic intervals (CDIs) and their maximum
gradients. CDI, the DI at which the gradient equals unity
[45], was calculated from the fitted function. Untreated
KCNE1
−/− hearts showed larger epicardial CDIs than WTs,
46.26±6.48 versus 9.76±1.06 ms (P<0.001; n=6 in both
cases). Similarly, larger CDIs were observed in the
endocardium of KCNE1
−/− hearts having a CDI of 50.26±
9.27 versus 16.02±2.73 ms in WT hearts (P<0.01; n=6 in
both cases). We therefore demonstrate larger CDIs in
KCNE1
−/− hearts compared to WT hearts and confirm this
in both epicardium and endocardium.
Maximum gradients of APD90 restitution curves were
then compared. In the epicardium of KCNE1
−/− hearts, the
maximum gradient was 1.32±0.18, significantly larger than
in WT hearts in which the maximum gradient was 0.59±
0.02 (P<0.01; n=6 in both cases). In the endocardium, the
maximum gradient was also larger in KCNE1
−/− hearts than
in WTs hearts, though this did not reach statistical
significance, with gradients of 1.11±0.21 versus 0.69±
Fig. 7 APD90 alternans recorded over a range of BCLs from the epicardium (a and c) and endocardium (b and d) of untreated (a and b) and
nicorandil-treated (20 µM) (c and d) KCNE1
−/− (a and c) and WT (b and d) hearts
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−/− and WT hearts, respectively (n=6 in
both cases).
Alterations in CDIs and maximum gradients correlate
with changes in arrhythmogenic tendencies in both
KCNE1
−/− and WT hearts
In view of the observed antiarrhythmic actions of nicorandil
in KCNE1
−/− hearts, we then quantified the effects of
nicorandil (20 µM), the highest concentration at which
significant antiarrhythmic effects were observed, upon
CDIs and maximum gradients for the first time in any
model of JLN. Nicorandil significantly reduced the CDI in
the epicardium of KCNE1
−/− hearts (Fig. 10a) from 46.26±
6.48 to −0.15±0.05 ms (P<0.001; n=6 in both cases). It
had a similar action upon the CDI in the endocardium of
KCNE1
−/− hearts, shortening the CDI from 50.26±9.27 to
26.94±4.65 (P<0.05; n=6 in both cases). The maximum
gradient was also significantly reduced in both the
epicardium, from 1.32±0.18 to 0.55±0.04 (P<0.01), and
appreciably but not significantly in the endocardium, from
1.11±0.21 to 0.76±0.07 (P>0.05) (Fig. 10c). In WT hearts,
nicorandil reduced the epicardial CDI (Fig. 10b), from
9.76±1.06 to −136.54±40.86 ms (P<0.05; n=6). Similarly,
nicorandil reduced the CDI in the endocardium of WT hearts
from 16.02±2.73 to −14.91±1.75 ms (P<0.001; n=6). It
also decreased the maximum gradient of restitution curves
in WT hearts (Fig. 10d). This occurred in the epicardium,
from 0.59±0.02 to 0.27±0.04 (P<0.001; n=6), and in the
endocardium, from 0.69±0.04 to 0.54±0.03 (P<0.05; n=6)
in untreated and nicorandil-treated WT hearts, respectively.
Thus, the enhanced arrhythmogenicity observed in
KCNE1
−/− hearts was associated with steeper epicardial
and endocardial restitution curves compared to WT hearts,
while reductions in arrhythmogenicity by nicorandil were
accompanied by reductions in such gradients.
Discussion
The experiments described in this study characterized
arrhythmic properties and their possible mechanisms at
the whole organ level by comparing isolated perfused
KCNE1
−/− with WT hearts. The primary abnormality in
the KCNE1
−/− murine system is a loss-of-function,
targeted deletion of the gene encoding the minK K
+
channel accessory β-subunit. In common with patients
Fig. 8 Epicardial restitution curves recorded from the epicardium of KCNE1
−/− (a and c) and WT (b and d) hearts perfused with control solution
(a and b) or 20 µM nicorandil (c and d)
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KCNE1
−/− mouse is known to possess inner ear defects,
manifesting as deafness and shaker/waltzer behavior,
attributed to deficient transepithelial K
+ secretion in the
stria vascularis and vestibular dark cells of the inner ear.
Histological appearances in the inner ears of KCNE1
−/−
mice [68] were also shown to be similar to those observed
in post-mortem inspections of the human condition [11].
Previous experiments in patch-clamped neonatal cardiac
myocytes, rather than whole heart investigations, had
suggested alterations in cardiac electrophysiology involv-
ing late as opposed to early (Ito)K
+ current in the
KCNE1
−/− cardiac system [9, 30]. These empirically
demonstrated reductions in the rapid component of the
delayed rectifier current (IKr)[ 30] relative to WT and a
total absence of the slow component, IKs [9, 30], albeit
from relatively low levels of detection in WTs. Corre-
spondingly, mRNA for minK was detectable at low levels
in WT but totally absent from KCNE1
−/− myocytes [9]. In
contrast, early outward currents (Ito) remained conserved
[30] as were mRNA levels [9] for the alpha subunit
KvLQT1 (which together with minK is responsible for IKs
[5, 21, 49]), Kv1.5 (the alpha subunit responsible for IKur
[70]) and mERG (the murine protein corresponding to the
human alpha subunit protein, HERG, that underlies IKr
[48]).
Table 1 Parameters used in curve fitting to experimentally obtained epicardial APD90 restitution data sets
ny 0 (ms) A (ms) τ (ms) χ
2 CDI (ms) Maximum gradient
KCNE1
−/− 6 −75.71±13.56 142.78±12.75 29.06±2.22 0.164 46.26±6.48 1.32±0.18
KCNE1
−/−+20 µM nicorandil 6 −4.18±6.56 68.33±2.80 68.48±16.28 0.152 −0.15±0.05 0.55±0.04
WT 6 −7.04±2.53 63.77±1.62 53.06±3.95 0.095 9.76±1.06 0.59±0.02
WT+20 µM nicorandil 6 10.6±1.5 50.0±4.0 136.2±27.8 0.060 −136.54±40.86 0.27±0.04
Fig. 9 Endocardial restitution curves recorded from the endocardium of KCNE1
−/− (a and c) and WT (b and d) hearts perfused with control
solution (a and b) or 20 µM nicorandil (c and d)
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reports that intact, perfused KCNE1
−/− mouse hearts
recapitulated cardiac features of the JLN2 variant of JLN
syndrome [20] in their enhanced susceptibility to VT. It
then related these properties to the presence of triggered
activity and to criteria for re-entrant excitation that
enabled the detection and separation of underlying re-
entrant substrates. We then both empirically tested the
efficacy of nicorandil as an antiarrhythmic agent in the
KCNE1
−/− murine model and related this to actions on
such re-entrant criteria for the first time. In doing so, we
empirically tested the idea that arrhythmogenicity could be
reduced by the action of nicorandil, which, at the higher
concentrations used in this study, has been shown to
shorten cardiac APDs in other cardiac preparations (see
the “Introduction” section) possibly through acting upon
K
+ conductance [18, 22, 57, 60], independent of external
Na
+, and in the absence of alterations in Ca
2+ currents [15,
22]. It has been suggested for use as a potentially antiarrhyth-
mic pharmacological agent in LQTS, supported by prelimi-
nary clinical studies in patients with LQT1 [58] and familial
[1] and idiopathic [13, 50] LQTS where the genotype had
not been determined. Experimental studies in a hypokalae-
mic murine model [26], a genetic murine LQT3 model [17],
a pharmacological guinea pig LQT1 model [76], and
pharmacological canine LQT1, LQT2, and LQT3 models
are also consistent with potential antiarrhythmic roles for
nicorandil [7, 57]. However, neither this antiarrhythmic
action nor its possible mechanisms at the level of intact
hearts have been specifically tested in any system modelling
loss-of-function mutations in KCNE1, whether obtained
through pharmacological or genetic modification or whether
in experimental or clinical situations. We used concentrations
(10 and 20 µM) comparable to those employed in earlier
reports of nicorandil-mediated reductions in repolarization
durations or suppressed arrhythmogenesis in other cardiac
Fig. 10 CDI (a and b) and maximum gradients (c and d) derived from restitution curves from the epicardium and endocardium of KCNE1
−/− (a
and c) and WT (b and d) hearts perfused with control solution or 20 µM nicorandil (*P<0.05; **P<0.01, ***P<0.001)
Table 2 Parameters used in curve fitting to experimentally obtained endocardial APD90 restitution data sets
ny 0 (ms) A (ms) τ (ms) χ
2 CDI (ms) Maximum gradient
KCNE1
−/− 6 104.89±21.81 159.31±20.84 30.25±2.78 0.654 50.26±9.27 1.11±0.21
KCNE1
−/−+20 µM nicorandil 6 −22.97±6.30 86.38±4.45 50.87±5.93 0.152 26.94±4.65 0.76±0.07
WT 6 −13.81±4.37 81.31±2.21 63.07±7.50 0.178 16.02±2.73 0.69±0.04
WT+20 µM nicorandil 6 6.89±1.44 66.89±1.28 80.50±6.61 0.081 −14.91±1.75 0.54±0.03
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tissue [57, 76], or whole organ levels [17, 26, 76].
Our experiments demonstrated both spontaneous and
provoked arrhythmogenesis in isolated perfused
KCNE1
−/− hearts. They complement earlier reports that
demonstrated altered electrocardiographic QT–heart rate
relationships in intact anesthetized animals compatible
with arrhythmogenic consequences [9] (but see [30]). A
further report did not observe provoked arrhythmogenesis
on the basis of optical recordings in Langendorff-perfused
hearts. However, that study [47] adopted left ventricular
apical rather than right ventricular stimulation, used longer
(200 ms instead of 125 ms) BCLs, employed differing
PES or burst stimulus protocols, and used C57Black6
rather than 129/Sv animals. Nevertheless, the arrhythmo-
genic properties described in the present paper closely
agree with previous studies that had employed stimulation
protocols and murine strains [4] that were comparable
both to those used in this study and to those used to
explore other murine models [25, 45]. These contrasts are
consistent with the suggestion that arrhythmogenic pro-
pensity may require particularly sensitive provocation
techniques for their detection [51].
The present experiments additionally applied a set of
criteria previously developed in the murine system [16, 25,
44, 64]. They were applied in both KCNE1
−/− and WT
hearts, in the absence and presence of nicorandil. This
application yielded parameters that were used to detect the
presence or absence of both spatial re-entrant substrate,
reflected in ∆APD90 and critical intervals for local re-
excitation, and temporal re-entrant substrate, reflected in
APD90 alternans and APD90 restitution properties.
Firstly, we demonstrated that intrinsically beating
KCNE1
−/−, but not WT hearts, showed spontaneous,
nicorandil-sensitive triggered activity that was accompanied
by longer runs of spontaneous VT. These had not been
sought in previous reports [4, 9, 30, 47] which had studied
electrocardiographic records, bipolar electrograms, or opti-
cal traces, rather than the MAP records used in this study.
Nevertheless, these observations agree with and extend a
recent description of MAP records which showed sponta-
neous nifedipine-sensitive abnormalities of repolarization
[66] .T h ep r e s e n ts t u d i e sg oo nt od e m o n s t r a t et h a t
nicorandil suppressed both the triggered activity and the
spontaneous VT.
Secondly, in contrast to WT, KCNE1
−/− hearts showed
evidence for abnormal spatial patterns of repolarization.
This took the form of increased epicardial, though
conserved endocardial, APD90s. This would in turn
perturb transmural gradients of repolarization by resulting
in reduced or even negative ∆APD90s. These findings
could be obtained from the measurements of both
endocardial and epicardial MAP, thereby adding to reports
that were confined to either electrocardiographic or optical
epicardial recordings [4, 9, 30, 47]. These results in
KCNE1
−/− hearts complement findings in other arrhyth-
mogenic murine systems modeling human LQT3 [64]a n d
acquired hypokalaemic LQTS [25]w h i c ha l s os h o w
prolonged epicardial relative to endocardial APD90.A l t e r e d
spatial patterns of repolarization have also been demonstrat-
ed in pharmacological models of LQTS involving the
arterially-perfused canine wedge [3]. Such alterations may
contribute to re-entrant arrhythmogenesis in view of the
relatively short distance across the thickness of the ventric-
ular free wall [3]. We went on to demonstrate that nicorandil
increased ∆APD90 by reducing the epicardial APD90 while
conserving the endocardial APD90 not only in KCNE1
−/− but
also in WT hearts. It thus corrected the alteration in
KCNE1
−/− hearts in the direction of and consequently
approximating WT values that had been observed in the
absence of nicorandil. Such region-dependent actions of
nicorandil upon epicardial rather than endocardial APD90
have been observed in a canine ischaemic model [32]a sw e l l
as in hypokalaemic murine hearts [26].
Thirdly, KCNE1
−/− hearts demonstrated larger local
critical intervals for re-excitation than WT hearts. This
paralleled their enhanced tendencies to spontaneous and
provoked arrhythmogenesis. Such intervals were derived
from the difference between APD90 and refractory period
and have also been correlated with arrhythmogenic pro-
pensity in hypokalaemic murine hearts [44]. Treatment with
nicorandil significantly reduced these critical intervals in
both KCNE1
−/− and WT hearts in parallel with reductions
in arrhythmic tendency in KCNE1
−/− hearts.
Fourthly, both KCNE1
−/− and WT hearts demonstrated
enhanced tendencies to APD90 alternans as derived from
differences in successive odd and even APD90 values with
decreasing BCL. However, such alternans was consistent-
ly greater in KCNE1
−/− than in WT hearts in both
epicardium and endocardium. Such trends have also been
observed in murine models for LQT3 and hypokalaemic
acquired LQTS [17, 45]. These findings also complement
a previous electrocardiographic study that reported a
development of T wave alternans (TWA) during
isoproterenol-mediated increases in heart rate. The latter
study did not observe differences between WT and
KCNE1
−/− hearts, but had studied relatively small numbers
of anesthetized, intact mutant (two mice) and WT
preparations (three mice) [9]. Furthermore, the properties
shown by our isolated denervated cardiac preparations
agree with and add to previous findings obtained under
comparable conditions but confined to a single basic cycle
length [66]. Previous analysis of human action potential
waveforms using MAP electrodes has directly correlated
A P Da l t e r n a n sw i t hT W Ai nL Q T S[ 59]. In general, APD
alternans is thought to underlie the TWA that has been
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latter in turn has been associated with enhanced arrhyth-
mogenic propensity not only in LQTS [54]b u ta l s oi na
wide variety of other arrhythmic settings, including
ischaemia, acidosis, and pharmacological agents (reviewed
in [34]). Our results go on to additionally demonstrate that
nicorandil reduced APD alternans in KCNE1
−/− hearts to
levels similar to WT hearts in both epicardium and
endocardium.
Fifthly, application of a dynamic pacing protocol [29]
to KCNE1
−/− hearts permitted quantification of MAP
waveforms in the steady-state achieved following intro-
duction of a range of given BCLs. This approach
successfully demonstrated that both epicardial and endo-
cardial APD90 restitution curves from KCNE1
−/− hearts
showed greater slopes than did WT hearts in parallel with
their arrhythmogenic tendencies. Establishing that such
properties exist in isolated hearts free of autonomic
innervation, as performed in this study, also complements
a previous electrocardiographic study that reported abnor-
mal adaptation of QT interval to heart rate in intact
anesthetized KCNE1
−/− mice [9]. However, this could not
examine the relationship between APD90 and DI. Our
findings contrast with measurements that had been
obtained using extrasystolic stimuli rather than exploring
a range of BCLs using a dynamic pacing protocol [47, 66].
Nevertheless, our results are likely to provide closer
representations of APD since our use of contact MAP
electrodes rather than optical measurements permitted
both epicardial and endocardial recordings and yielded
APD90 rather than APD75 values. This enabled relation-
ships between APD90 and DI rather than APD75 and BCL
to be investigated. This in turn permitted the graphical
analysis introduced by Nolasco and Dahlens that permit-
ted us to establish whether there existed a CDI at which
APD90 varied with DI in a manner compatible with re-
entrant arrhythmogenesis [39, 72]. The present studies
consequently add to previous demonstrations of temporal
re-entrant substrate in other arrhythmogenic murine heart
models for LQT3 and Brugada syndrome [17, 46]a n d
hypokalaemic VT [45]. Our results also demonstrated that
nicorandil treatment reduced these gradients in both
KCNE1
−/− and WT hearts in parallel with its reduction
of arrhythmogenic tendency.
KCNE1
−/− hearts thus provided us with a valuable
arrhythmogenic model exhibiting not only spontaneous
but also PES-induced VT. They showed accompanying
spontaneous triggered activity as well as measurable spatial
and temporal heterogeneities in MAP waveform that could
potentially underlie such arrhythmogenic tendencies. The
present experiments went on to confirm such a hypothesis
by demonstrating that an introduction of nicorandil pro-
duced a parallel abolition of all these properties. This was
consistent with a participation of both triggered activity and
spatial and temporal re-entrant substrate in the properties
observed.
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